A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis

Journal of Molecular and Cellular Cardiology

Volumn 98, Issue , 2016, Pages 37-47

  Kawase, Haruya ^a   Bando, Yasuko K ^a   Nishimura, Kazuyuki ^a   Aoyama, Morihiko ^a   Monji, Akio ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Cardiac remodeling; Dipeptidyl peptidase 4 inhibitor; Hypertension; Sodium proton pump exchanger

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL PEPTIDASE IV; NEUROPEPTIDE Y; SODIUM PROTON EXCHANGE PROTEIN 1; TENELIGLIPTIN; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GROWTH FACTOR-ACTIVATABLE NA-H EXCHANGER NHE-1; PYRAZOLE DERIVATIVE; SODIUM PROTON EXCHANGE PROTEIN; THIAZOLIDINE DERIVATIVE;

ACIDIFICATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC REMODELING; CLINICAL FEATURE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; GENE SILENCING; HEART DISEASE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PROTECTION; HYPERTENSION; LUNG CONGESTION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; UPREGULATION; ANIMAL; BLOOD PRESSURE; CARDIAC MUSCLE CELL; DISEASE MODEL; DRUG EFFECTS; ECHOCARDIOGRAPHY; GENETICS; HEART FAILURE; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; VASODILATATION;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; HEART FAILURE; HYPERTENSION; MALE; MYOCYTES, CARDIAC; PYRAZOLES; RATS; RATS, INBRED SHR; SIGNAL TRANSDUCTION; SODIUM-HYDROGEN ANTIPORTER; THIAZOLIDINES; VASODILATION; VENTRICULAR REMODELING;

EID: 84978877751     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.06.066     Document Type: Article

References (54)

1. [1] Hampp, C., Borders-Hemphill, V., Moeny, D.G., Wysowski, D.K., Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care 37 (2014), 1367–1374.
2. [2] Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373 (2015), 232–242.
3. [3] White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369 (2013), 1327–1335.
4. [4] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369 (2013), 1317–1326.
5. [5] Filion, K.B., Azoulay, L., Platt, R.W., Dahl, M., Dormuth, C.R., Clemens, K.K., et al. A multicenter observational study of incretin-based drugs and heart failure. N. Engl. J. Med. 374 (2016), 1145–1154.
6. [6] McGuire, D.K., Van de Werf, F., Armstrong, P.W., Standl, E., Koglin, J., Green, J.B., et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol., 1, 2016, 126.
7. [7] Liu, L., Liu, J., Wong, W.T., Tian, X.Y., Lau, C.W., Wang, Y.X., et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60 (2012), 833–841.
8. [8] Devin, J.K., Pretorius, M., Nian, H., Yu, C., Billings, F.T., Brown, N.J., Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension 63 (2014), 951–957.
9. [9] Jackson, E.K., Mi, Z., Tofovic, S.P., Gillespie, D.G., Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. Hypertension 65 (2015), 238–249.
10. [10] Maron, B.A., Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension. Can. J. Cardiol. 31 (2015), 515–520.
11. [11] Kollias, A., Lagou, S., Zeniodi, M.E., Boubouchairopoulou, N., Stergiou, G.S., Association of central versus brachial blood pressure with target-organ damage: systematic review and meta-analysis. Hypertension 67 (2016), 183–190.
12. [12] Nabeno, M., Akahoshi, F., Kishida, H., Miyaguchi, I., Tanaka, Y., Ishii, S., et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem. Biophys. Res. Commun. 434 (2013), 191–196.
13. [13] Morishita, R., Nakagami, H., Teneligliptin: expectations for its pleiotropic action. Expert. Opin. Pharmacother. 16 (2015), 417–426.
14. [14] Reid, A.C., Mackins, C.J., Seyedi, N., Levi, R., Silver, R.B., Coupling of angiotensin II AT1 receptors to neuronal NHE activity and carrier-mediated norepinephrine release in myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol. 286 (2004), H1448–H1454.
15. (+) exchanger activity and cardiac remodeling following pressure overload. Basic Res. Cardiol., 107, 2012, 236.
16. [16] Shigeta, T., Aoyama, M., Bando, Y.K., Monji, A., Mitsui, T., Takatsu, M., et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 126 (2012), 1838–1851.
17. [17] Zaruba, M.M., Theiss, H.D., Vallaster, M., Mehl, U., Brunner, S., David, R., et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4 (2009), 313–323.
18. [18] Lambeir, A.M., Durinx, C., Scharpe, S., De Meester, I., Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40 (2003), 209–294.
19. [19] Forstermann, U., Sessa, W.C., Nitric oxide synthases: regulation and function. Eur. Heart J. 33 (2012), 829–837 (37a–37d).
20. [20] Kim, M., Platt, M.J., Shibasaki, T., Quaggin, S.E., Backx, P.H., Seino, S., et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 19 (2013), 567–575.
21. [21] Zaman, M.A., Oparil, S., Calhoun, D.A., Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov. 1 (2002), 621–636.
22. [22] Emdin, M., Fatini, C., Mirizzi, G., Poletti, R., Borrelli, C., Prontera, C., et al. Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. Clin. Chim. Acta 443 (2015), 85–93.
23. [23] Volpe, M., Unger, T., Plasma renin and cardiovascular risk: what is the evidence for an association?. Cardiology 125 (2013), 50–59.
24. [24] Sealey, J.E., Alderman, M.H., Furberg, C.D., Laragh, J.H., Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am. J. Hypertens. 26 (2013), 727–738.
25. [25] Brown, N.J., Byiers, S., Carr, D., Maldonado, M., Warner, B.A., Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 54 (2009), 516–523.
26. [26] Gillum, R.F., Teichholz, L.E., Herman, M.V., Gorlin, R., The idiopathic hyperkinetic heart syndrome: clinical course and long-term prognosis. Am. Heart J. 102 (1981), 728–734.
27. [27] Davis, J.T., Rao, F., Naqshbandi, D., Fung, M.M., Zhang, K., Schork, A.J., et al. Autonomic and hemodynamic origins of pre-hypertension: central role of heredity. J. Am. Coll. Cardiol. 59 (2012), 2206–2216.
28. [28] Zucker, I.H., Xiao, L., Haack, K.K., The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. Clin. Sci. (Lond.) 126 (2014), 695–706.
29. [29] Matsui, H., Barry, W.H., Livsey, C., Spitzer, K.W., Angiotensin II stimulates sodium-hydrogen exchange in adult rabbit ventricular myocytes. Cardiovasc. Res. 29 (1995), 215–221.
30. [30] Karmazyn, M., Kilic, A., Javadov, S., The role of NHE-1 in myocardial hypertrophy and remodelling. J. Mol. Cell. Cardiol. 44 (2008), 647–653.
31. [31] Ruilope, L.M., Schmieder, R.E., Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am. J. Hypertens. 21 (2008), 500–508.
32. [32] Mancini, G.B., Dahlof, B., Diez, J., Surrogate markers for cardiovascular disease: structural markers. Circulation 109 (2004), IV22–IV30.
33. [33] Verdecchia, P., Schillaci, G., Borgioni, C., Ciucci, A., Battistelli, M., Bartoccini, C., et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J. Am. Coll. Cardiol. 25 (1995), 871–878.
34. [34] de Simone, G., Kizer, J.R., Chinali, M., Roman, M.J., Bella, J.N., Best, L.G., et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the strong heart study. Am. J. Hypertens. 18 (2005), 191–196.
35. [35] Kahan, T., Bergfeldt, L., Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart 91 (2005), 250–256.
36. [36] Okin, P.M., Devereux, R.B., Jern, S., Kjeldsen, S.E., Julius, S., Nieminen, M.S., et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation 108 (2003), 684–690.
37. [37] Hollenberg, N.K., Fisher, N.D., Price, D.A., Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32 (1998), 387–392.
38. [38] Kumar, R., Singh, V.P., Baker, K.M., The intracellular renin-angiotensin system: implications in cardiovascular remodeling. Curr. Opin. Nephrol. Hypertens. 17 (2008), 168–173.
39. [39] Schmieder, R.E., Langenfeld, M.R., Friedrich, A., Schobel, H.P., Gatzka, C.D., Weihprecht, H., Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 94 (1996), 1304–1309.
40. [40] Sim, J.J., Bhandari, S.K., Shi, J., Kalantar-Zadeh, K., Rasgon, S.A., Sealey, J.E., et al. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. Am. J. Hypertens. 25 (2012), 379–388.
41. [41] Marney, A., Kunchakarra, S., Byrne, L., Brown, N.J., Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 56 (2010), 728–733.
42. [42] Shanks, J., Manou-Stathopoulou, S., Lu, C.J., Li, D., Paterson, D.J., Herring, N., Cardiac sympathetic dysfunction in the prehypertensive spontaneously hypertensive rat. Am. J. Physiol. Heart Circ. Physiol. 305 (2013), H980–H986.
43. [43] Hoit, B.D., Shao, Y., Kinoshita, A., Gabel, M., Husain, A., Walsh, R.A., Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J. Clin. Invest. 95 (1995), 1519–1527.
44. [44] Kumar, R., Boim, M.A., Diversity of pathways for intracellular angiotensin II synthesis. Curr. Opin. Nephrol. Hypertens. 18 (2009), 33–39.
45. [45] Yahiro, E., Miura, S., Imaizumi, S., Uehara, Y., Saku, K., Chymase inhibitors. Curr. Pharm. Des. 19 (2013), 3065–3071.
46. [46] Cheng, X.W., Huang, Z., Kuzuya, M., Okumura, K., Murohara, T., Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 58 (2011), 978–986.
47. [47] Uehara, Y., Miura, S., Yahiro, E., Saku, K., Non-ACE pathway-induced angiotensin II production. Curr. Pharm. Des. 19 (2013), 3054–3059.
48. [48] Sufiun, A., Rafiq, K., Fujisawa, Y., Rahman, A., Mori, H., Nakano, D., et al. Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hypertens. Res. 38 (2015), 237–243.
49. [49] Costa-Pessoa, J.M., Figueiredo, C.F., Thieme, K., Oliveira-Souza, M., The regulation of NHE(1) and NHE(3) activity by angiotensin II is mediated by the activation of the angiotensin II type I receptor/phospholipase C/calcium/calmodulin pathway in distal nephron cells. Eur. J. Pharmacol. 721 (2013), 322–331.
50. [50] Reshkin, S.J., Bellizzi, A., Caldeira, S., Albarani, V., Malanchi, I., Poignee, M., et al. Na +/H + exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J. 14 (2000), 2185–2197.
51. [51] Sipahi, I., Debanne, S.M., Rowland, D.Y., Simon, D.I., Fang, J.C., Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 11 (2010), 627–636.
52. [52] Mihaila, R.G., A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 159 (2015), 519–526.
53. [53] Yagi, S., Aihara, K., Ikeda, Y., Sumitomo, Y., Yoshida, S., Ise, T., et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ. Res. 102 (2008), 68–76.
54. [54] Kudo, S., Satoh, K., Nogi, M., Suzuki, K., Sunamura, S., Omura, J., et al. SmgGDS as a crucial mediator of the inhibitory effects of statins on cardiac hypertrophy and fibrosis: novel mechanism of the pleiotropic effects of statins. Hypertension 67 (2016), 878–889.